NAD+ injections and intravenous drips are currently widely offered by wellness clinics, med-spas, IV therapy centers, and some telehealth providers. They are most commonly promoted in the context of energy, recovery, and anti-aging.
However, commercial popularity is not the same as clinical validation.
Intravenous NAD+ has been studied for specific medical applications, and some providers also offer intramuscular and subcutaneous forms. At the same time, standard wellness protocols currently used in clinics have significantly less controlled human trial data than oral NAD+ precursors such as NR and NMN.
In this guide, we explain what NAD+ injections and infusions are, how the various administration routes differ, what to expect before, during, and after a session, what reactions have been reported, and how the available evidence compares to oral supplementation.
What is an NAD+ infusion or injection?
NAD+ can be administered intravenously, intramuscularly, or subcutaneously. All of these routes bypass the digestive tract, but they differ in administration method, infusion rate, volume, required monitoring, and the amount of available research.
The term „NAD+ injections” usually refers to two main approaches.
The first is intravenous infusion.
During IV administration, NAD+ is slowly delivered directly into the vein over a specified period of time.
The second approach is intramuscular or subcutaneous injections.
Intramuscular administration consists of introducing a solution into muscle tissue, whereas in subcutaneous administration, the solution goes into the adipose tissue located under the skin.
These routes usually use a smaller volume and require significantly less time than an intravenous infusion.
In clinical trials, intravenous NAD+ was used according to precisely defined protocols.
For example, in one randomized, placebo-controlled trial in patients with heart failure, 10 mg of NAD+ was administered intravenously daily for seven days, alongside standard heart failure treatment. [1]
Such a research protocol differs significantly from larger-amount NAD+ infusions offered during single sessions in wellness clinics.
Commercial infusions are often described as lasting from about an hour to several hours and may be offered as a single session or a series of repeated visits.
What is important, however, is that such commercial schemes have not been standardized on the basis of the same type of peer-reviewed clinical trials.
The amount of NAD+ administered during a single session, infusion speed, treatment frequency, and total therapy duration can therefore vary significantly between providers.
IV infusion vs. intramuscular or subcutaneous NAD+ injection: what's the difference?
Intravenous, intramuscular, and subcutaneous NAD+ bypass digestion in the gastrointestinal tract.
However, they do not provide an identical way of delivering the compound to the body.
NAD+ IV infusion
An intravenous infusion delivers NAD+ directly into the bloodstream through a vein.
A small catheter is usually placed in a vein in the hand or arm and connected to an infusion bag containing the prepared solution.
From the administration route perspective, one of the main advantages is the ability to control the infusion rate.
The solution can be administered gradually, allowing clinical staff to change the rate if unpleasant symptoms appear.
Intravenous administration also makes it possible to use a larger fluid volume than would typically be practical for a single intramuscular or subcutaneous injection.
This route of administration appeared in some clinical trials, including the previously described controlled heart failure study. [1]
It is also the dominant method used by commercial clinics offering NAD+ infusions.
Intramuscular NAD+ injection
Intramuscular administration involves injecting NAD+ directly into muscle tissue using a needle and syringe.
The material is then absorbed from the muscle into the circulation.
The entire procedure is usually much shorter than an IV session because it does not require a prolonged infusion.
At the same time, the volume of solution that can be practically administered in a single injection is more limited.
Subcutaneous NAD+ injection
When administered subcutaneously, the solution goes into the layer of fat tissue located under the skin.
This route is also used for many other injectable preparations because it allows the use of relatively small needles and usually requires a less elaborate procedure than an intravenous infusion.
Some telemedical services now offer subcutaneous NAD+ preparations intended for home use.
However, published clinical data regarding such contemporary home-use NAD+ protocols remains limited.
The simplest distinction is therefore as follows:
An IV infusion provides direct and gradual delivery of NAD+ into the bloodstream.
An intramuscular injection requires the absorption of the compound from the muscle.
A subcutaneous injection requires absorption from the tissue located beneath the skin.
All three methods bypass digestion, but merely bypassing the digestive tract does not prove greater clinical efficacy.
What can be expected before, during, and after NAD+ administration?
The course of an NAD+ session depends on the route of administration, the amount of the preparation, the infusion rate, the provider's procedures, and individual response.
Before the session
Administering NAD+ in a clinic usually begins with some form of health assessment.
It may include questions about medications taken, allergies, a history of cardiovascular disease, chronic illnesses, and previous reactions to injections or intravenous therapies.
Proper hydration may also be discussed prior to the IV infusion.
The scope of such an assessment varies between providers, which is another reason why it should not be assumed that commercial NAD+ administration follows a single standardized protocol.
During the IV infusion
The catheter is usually placed in a vein of the hand or arm.
Next, the NAD+ solution is administered gradually.
Some individuals report unpleasant systemic symptoms during the infusion.
They can include hot flashes, nausea, abdominal discomfort, a feeling of tightness in the chest, or other sensations that may become more noticeable with faster administration.
For this reason, the staff may decrease the infusion rate if symptoms appear.
The relationship between tolerance and infusion rate is one of the reasons why IV NAD+ sessions can take significantly longer than other types of IV therapy.
During an intramuscular or subcutaneous injection
Intramuscular and subcutaneous injections are usually much shorter procedures.
Instead of remaining connected to an IV line, the person receives a measured amount of the preparation in a single injection.
Local soreness, burning, or mild discomfort may occur at the injection site.
Because the administration is faster and involves a smaller volume, the visit itself can be much shorter than an IV session.
After administration
Feelings after administration can vary significantly.
An IV infusion naturally requires more time, as the infusion itself can take anywhere from less than an hour to several hours, depending on the protocol used.
Visits involving a single injection are usually much shorter.
In retrospective real-world data, gastrointestinal and cardiac symptoms were reported more frequently with IV NAD+ than with intravenous nicotinamide riboside. [2]
These results do not allow predicting each person's reaction, but are important in assessing what may occur during or after the infusion.
Injection site reactions and other reported symptoms
Local reactions can occur with virtually any preparation administered by injection or intravenously.
NAD+ is no exception.
Mild redness, swelling, tenderness, bruising, pain, or temporary burning may occur at the needle or catheter insertion site.
They must be distinguished from systemic reactions.
Systemic symptoms refer to reactions extending beyond the injection site itself.
In a retrospective study comparing IV NAD+ to intravenous nicotinamide riboside, gastrointestinal and cardiac-related symptoms were more frequently reported in the NAD+ group. [2]
Reported gastrointestinal symptoms included nausea and abdominal cramps, among others.
Among the ailments related to the circulatory system, heart palpitations and chest discomfort were described.
Such symptoms have greater clinical significance than mild bruising or tenderness at the injection site.
Their occurrence may also be influenced by the infusion rate and the amount of the administered preparation.
Therefore, significant chest discomfort, persistent nausea, pronounced dizziness, palpitations, or other significant symptoms during the infusion should not simply be treated as a normal part of an NAD+ session.
They should be immediately reported to the medical personnel supervising the procedure.
NAD+ administered in a clinic vs. at-home injections
NAD+ is currently offered both in traditional clinical settings and through telemedicine services delivering injectable preparations for home use.
Both approaches create very different practical conditions.
NAD+ administered in the clinic
Administration in the clinic allows medical staff to directly supervise the procedure.
This is of particular importance with IV infusions, as a session can last several hours and the infusion rate may need to be adjusted if symptoms occur.
Staff is also available to assess unexpected reactions.
The drawbacks are mainly of a practical nature.
Treatment at a clinic typically requires scheduling an appointment, travel, more time, and higher costs for a single session due to the involvement of staff and facility infrastructure.
NAD+ injections at home
Some telehealth providers offer subcutaneous NAD+ intended for self-administration at home.
Such a solution is more convenient and can reduce costs associated with regular clinic visits.
However, self-administration shifts a number of responsibilities to the user.
They include correct measurement of the preparation, proper injection technique, rotating injection sites, hygienic handling of the preparation, safe disposal of needles, and recognition of symptoms requiring medical attention.
Published clinical studies on contemporary home NAD+ injection programs remain sparse.
Therefore, the mere availability of commercial products for self-injection should not be equated with a confirmed clinical basis regarding their long-term efficacy or safety.
The quality of the preparation is also an important issue.
Products intended for injection require higher standards of sterility and contamination control than regular oral supplements, because they bypass many of the body's external protective barriers.
Whether the preparation is administered in a clinic or delivered to home, its identity, purity, sterility, storage conditions, and manufacturing quality matter.
Are NAD+ injections better than oral supplements?
NAD+ injections and infusions are often promoted as more effective because they bypass digestion in the gastrointestinal tract.
Such reasoning seems simple, but controlled human study data presents a more complex picture.
Oral NAD+ precursors, such as nicotinamide riboside and nicotinamide mononucleotide, have been evaluated in numerous randomized, placebo-controlled trials. [3–6]
These studies consistently show that oral NR and NMN can increase circulating NAD+ or levels of related metabolites.
These compounds also generally showed good tolerability in the short and medium term covered by the studies.
However, the functional results were less consistent.
Increasing NAD+ does not automatically lead to an improvement in every investigated metabolic, cardiovascular, physical performance, or cognitive function parameter.
Nevertheless, oral precursors have a significantly larger base of controlled clinical trials than direct NAD+ injections.
Evidence regarding IV and injectable NAD+
A 2026 systematic review of NAD+ interventions found no eligible human controlled trials directly evaluating intravenous or intramuscular NAD+ for general anti-aging or wellness applications. [7]
This is particularly important because it is precisely in these areas that these methods are widely promoted.
Clinical trials on intravenous NAD+ exist in specific medical contexts.
One example is the previously described controlled trial concerning heart failure. [1]
However, the applied protocol involved a specific group of patients, a relatively small dose of 10 mg of NAD+ per day, a seven-day intervention period, and concurrent standard treatment.
This study should not be treated as confirmation of the much broader commercial IV NAD+ protocols used in wellness clinics.
Direct administration does not automatically mean better evidence
Bypassing the gastrointestinal tract changes the route of administration.
Does not automatically prove greater effectiveness.
To demonstrate the superiority of IV or injectable NAD+ over oral NR or NMN, direct studies comparing pharmacokinetics, cellular uptake, relevant biomarkers, clinical outcomes, adverse effects, and long-term safety under equivalent conditions would be needed.
Such data remains limited.
Current evidence therefore supports a more cautious conclusion.
NAD+ injections and infusions allow for direct systemic administration, but oral NR and NMN currently have a stronger foundation of randomized human trials supporting their ability to increase NAD+-related biomarkers.
IV NAD+ vs NAD+ injections vs oral precursors
| Feature | IV NAD+ | Intramuscular/subcutaneous NAD+ | Oral NR/NMN |
|---|---|---|---|
| Application route | Directly into the vein | Muscle or subcutaneous tissue | Gastrointestinal absorption |
| Omija digestion | Yes | Yes | Not |
| Typical serving suggestion | Slow infusion | Single injection | Capsule, tablet, or powder |
| Session time | Usually longer | Short | No clinical session required |
| Clinical supervision | Usually continuous | Clinic or home, depending on the provider | Usually not required |
| Randomized human trials | Limited and apply to specific diseases | Very limited | Strongest evidence base |
| Controlled anti-aging/wellness trials | No eligible studies in the 2026 review [7] | No eligible studies in the 2026 review [7] | Many controlled studies on precursors [3–6] |
| The demonstrated increase in NAD+ biomarkers | Biologically plausible, but wellness data limited | Limited direct data | Yes, demonstrated multiple times |
| Reported tolerance issues | Gastrointestinal and cardiac symptoms in a retrospective study [2] | Local and systemic effects are not well characterized | Generally good tolerance in studies |
| Home use | Not | Increasingly offered | Common |
| Proof of superiority over oral precursors | Not demonstrated | Not demonstrated | — |
Therefore, the main difference does not come down to whether a given compound bypasses the digestive tract.
Much more important is the depth and quality of the evidence for each route of administration.
Frequently asked questions about NAD+ injections and IV infusions
What happens during an IV NAD+ infusion?
A catheter is placed in a vein, and the NAD+ solution is administered gradually.
Commercial sessions can last from under an hour to several hours, depending on the amount of the preparation and the infusion rate.
Some individuals report nausea, hot flashes, chest tightness, abdominal discomfort, or similar sensations during the infusion, especially with faster administration. [2]
Are NAD+ injections and NAD+ IV drips the same thing?
No.
IV administration delivers NAD+ directly into the bloodstream through a vein.
With an intramuscular or subcutaneous injection, NAD+ first goes into the tissue, from which it must then be absorbed into the circulation.
Therefore, these methods differ in both their route of administration and pharmacokinetic profile.
Do IV NAD+ infusions have clinically proven anti-aging effects?
There is currently no solid controlled evidence confirming IV NAD+ as an anti-aging method.
A 2026 systematic review found no eligible controlled trials regarding intravenous or intramuscular NAD+ for anti-aging or wellness applications. [7]
Has intravenous NAD+ been clinically studied?
Yes, but in certain contexts.
For example, in a randomized trial on heart failure, 10 mg of NAD+ was administered intravenously every day for seven days along with standard treatment. [1]
Such a protocol does not confirm the effectiveness of larger commercial wellness infusions offered by private clinics.
Are NAD+ injections better than NMN or NR?
This has not been demonstrated.
Oral NR and NMN have a larger base of randomized placebo-controlled trials observing an increase in NAD+-related biomarkers. [3–6]
There is a lack of direct comparative studies confirming greater clinical effects of injectable NAD+.
Can IV NAD+ cause side effects?
Systemic symptoms were reported.
In a retrospective comparison, gastrointestinal and cardiac-related symptoms were observed more frequently with IV NAD+ than with intravenous nicotinamide riboside. [2]
Because this was a retrospective study, it does not allow for determining the exact frequency of such reactions for all NAD+ infusion protocols.
Can NAD+ be injected at home?
Some telemedicine services offer subcutaneous NAD+ preparations intended for home use.
However, published research regarding such contemporary home protocols remains limited.
Self-injections also involve issues related to technique, hygiene and sterility, correct measurement of the preparation, storage, disposal of needles, and recognition of reactions requiring medical attention.
Are injection site reactions normal?
Following an injection or IV catheter insertion, mild redness, tenderness, bruising, swelling, or temporary discomfort may occur.
Such local reactions should be distinguished from systemic symptoms, such as chest discomfort, significant nausea, dizziness, or palpitations.
Limitations of current evidence
One of the main limitations is the difference between commercial NAD+ protocols and those used in research.
Wellness clinics may use varying amounts of the preparation, infusion rates, treatment frequencies, and session lengths, whereas published studies typically evaluate precisely defined interventions in specific populations.
In the controlled heart failure study described here, 10 mg of IV NAD+ was administered daily for seven days. [1]
It should not be assumed that the results of this study represent or confirm significantly different IV protocols commonly promoted in the context of energy, regeneration, longevity, or general wellness.
Another limitation is the tolerance data.
The comparison between IV NAD+ and intravenous nicotinamide riboside came from a retrospective pilot study conducted in real-world practice, rather than a randomized clinical trial. [2]
This means that the observed differences in gastrointestinal and cardiac symptoms may serve as an early signal, but do not allow for the establishment of a definitive comparative safety profile.
The evidence base for intramuscular and subcutaneous NAD+ is even smaller.
Published clinical research on modern injectable forms used in wellness clinics or home telemedicine programs remains limited.
According to a 2026 systematic review, there were no eligible controlled human studies evaluating specifically IV or intramuscular NAD+ for anti-aging or general wellness applications. [7]
Finally, bypassing gastrointestinal absorption should not be equated with a proven clinical advantage.
Direct comparative studies are still needed to show whether IV or injectable NAD+ leads to more significant biological or clinical effects than better-studied oral precursors such as NR or NMN.
Disclaimer
This article is for educational and scientific-information purposes only. It does not constitute medical advice, instructions for dosage or injection, administration guidelines, therapeutic recommendations, or a recommendation for the use of NAD+ intravenously, intramuscularly, subcutaneously, or via any other route.
NAD+ injections and infusions have significantly fewer controlled human study data regarding general wellness, anti-aging, energy, or recovery than their widespread commercial availability might suggest. Results obtained in specific clinical protocols should not be automatically translated to commercial infusion programs utilizing larger quantities, different administration rates, or distinct dosing schedules.
NAD+ injections and infusions are not approved by the FDA or EMA as treatments, preventatives, or cures for diseases. Injectable products also involve additional concerns regarding sterility, contamination, dosage accuracy, vascular or injection-site complications, and systemic reactions. Any intervention involving injectable or intravenous NAD+ should be considered solely under the supervision of a properly qualified healthcare professional. Pregnant or breastfeeding individuals, those with cardiovascular conditions or other significant medical issues, and those taking prescription medications should obtain individual medical advice before considering such interventions. Pain or significant chest pressure, severe or persistent nausea, marked dizziness, heart palpitations, difficulty breathing, fainting, or other serious symptoms occurring during or after an injection or infusion require urgent medical evaluation.
References
[1] American Journal of Cardiovascular Drugs. (2026). Effect of nicotinamide adenine dinucleotide on heart failure caused by ischemic cardiomyopathy: A randomized, placebo-controlled trial. American Journal of Cardiovascular Drugs. https://pmc.ncbi.nlm.nih.gov/articles/PMC12779688/
[2] Reyna, K., Heinzen, G., Patel, N., Ritter, M., Siojo, A., Legere, H., & Pojednic, R. (2026). Intravenous infusion of nicotinamide adenine dinucleotide (NAD+) versus nicotinamide riboside (NR): A retrospective tolerability pilot study in a real-world setting. Frontiers in Aging, 7, 1652582. https://doi.org/10.3389/fragi.2026.1652582
[3] Yi, L., Maier, A. B., Tao, R., Lin, Z., Vaidya, A., Pendse, S., Thasma, S., Andhalkar, N., Avhad, G., & Kumbhar, V. (2022). The efficacy and safety of β-nicotinamide mononucleotide (NMN) supplementation in healthy middle-aged adults: A randomized, multicenter, double-blind, placebo-controlled, parallel-group, dose-dependent clinical trial. GeroScience, 45, 29–43. https://doi.org/10.1007/s11357-022-00705-1
[4] Martens, C. R., Denman, B. A., Mazzo, M. R., Armstrong, M. L., Reisdorph, N., McQueen, M. B., Chonchol, M., & Seals, D. R. (2018). Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults. Nature Communications, 9, 1286. https://doi.org/10.1038/s41467-018-03421-7
[5] Conze, D., Brenner, C., & Kruger, C. L. (2019). Safety and metabolism of long-term administration of NIAGEN (nicotinamide riboside chloride) in a randomized, double-blind, placebo-controlled clinical trial of healthy overweight adults. Scientific Reports, 9, 9772. https://doi.org/10.1038/s41598-019-46120-z
[6] Dellinger, R. W., Santos, S. R., Morris, M., Evans, M., Alminana, D., Guarente, L., & Marcotulli, E. (2017). Repeat dose NRPT (nicotinamide riboside and pterostilbene) increases NAD+ levels in humans safely and sustainably: A randomized, double-blind, placebo-controlled study. npj Aging and Mechanisms of Disease, 3, 17. https://doi.org/10.1038/s41514-017-0016-9
[7] Gallagher, C., & Emmanuel, O. O. (2026). NAD+ supplementation for anti-aging and wellness: A PRISMA-guided systematic review of preclinical and clinical evidence. Ageing Research Reviews, 116, 103057. https://doi.org/10.1016/j.arr.2026.103057